TRIMETHYL GLYCINE (CID 248) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(3)
 
 
Inactive(127)
 
 
Inconclusive(8)
 
 
Unspecified(32)
 
 
Top Targets:
p450(10)
 
 
 
7TM GPCR Srx(4)
 
 
PIKKc TOR(4)
 
 
Pyruvate Kina..(4)
 
 
Pyr redox dim(4)
 
 
BioAssay Types:
Confirmatory(119)
 
 
 
Literature(34)
 
 
 
 
BioActivity Types:
Potency(98)
 
 
 
IC50(1)
 
 
Ki(1)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 161    Data Row: 170   Total Pages: 4   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID46393177]
 Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Crystal Structure Of Prox From Archeoglobus Fulgidus In Complex With Glycine Betaine [gi:55669782]
View
2
[SID46393864]
 Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Crystal Structure Of The Binding Protein Opuac In Complex With Glycine Betaine [gi:93278789]
View
3
[SID46393060]
 Experimentally measured binding affinity data derived from PDB [AID1811, Type: Literature]Chain A, Structure Analysis Of Prox In Complex With Glycine Betaine [gi:46015450]
View
4
[SID103312672]
Ki 1900Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting [AID630741, Type: Literature]Proton-coupled amino acid transporter 1 [gi:51316800]
View
5
[SID103312672]
IC50 8000Inhibitory activity against Plasmodium falciparum [AID158688, Type: Literature]
View
6
[SID103312672]
 Osmoprotective activity of compound in Rhizobium meliloti 102F34 by restoring its growth rate was evaluated; Highly osmoprotective [AID200206, Type: other]
View
7
[SID103312672]
 Tested for effect on doubling time of growth of Sinorhizobium meliloti 102F34 in Lactate aspartate(LAS) minimal medium (with addition of NaCl) [AID204967, Type: Literature]
View
8
[SID103312672]
 Tested for effect on doubling time of growth of Sinorhizobium meliloti 102F34 in Lactate aspartate(LAS) minimal medium (without addition of NaCl) [AID204968, Type: Literature]
View
9
[SID103312672]
 Maximal attenuance reached in the stationary phase was reported against Sinorhizobium meliloti 102F34 in Lactate aspartate(LAS) minimal medium (with addition of NaCl) [AID204969, Type: Literature]
View
10
[SID103312672]
 Maximal attenuance reached in the stationary phase was reported against Sinorhizobium meliloti 102F34 in Lactate aspartate(LAS) minimal medium (without addition of NaCl) [AID204970, Type: Literature]
View
11
[SID103312672]
 Evaluated for substrate specificity of betaine uptake in salt-stressed Sinorhizobium meliloti. compound to substrate ratio 100:1 [AID229696, Type: Literature]
View
12
[SID103312672]
 Evaluated for substrate specificity of betaine uptake in salt-stressed Sinorhizobium meliloti. compound to substrate ratio 10:1 [AID229697, Type: Literature]
View
13
[SID103312672]
 Evaluated for substrate specificity of betaine uptake in salt-stressed Sinorhizobium meliloti. compound to substrate ratio 1:1 [AID229698, Type: Literature]
View
14
[SID103312672]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans [AID588211, Type: Literature]
View
15
[SID103312672]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents [AID588212, Type: Literature]
View
16
[SID103312672]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents [AID588213, Type: Literature]
View
17
[SID103312672]
 Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset [AID588220, Type: Literature]
View
18
[SID103312672]
 FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI [AID625278, Type: Literature]
View
19
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia [AID625279, Type: Literature]
View
20
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis [AID625280, Type: Literature]
View
21
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis [AID625281, Type: Literature]
View
22
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis [AID625282, Type: Literature]
View
23
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests [AID625283, Type: Literature]
View
24
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure [AID625284, Type: Literature]
View
25
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis [AID625285, Type: Literature]
View
26
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis [AID625286, Type: Literature]
View
27
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly [AID625287, Type: Literature]
View
28
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice [AID625288, Type: Literature]
View
29
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease [AID625289, Type: Literature]
View
30
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty [AID625290, Type: Literature]
View
31
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal [AID625291, Type: Literature]
View
32
[SID103312672]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score [AID625292, Type: Literature]
View
33
[SID103312672]
 Inhibitory activity against growth of Escherichia coli MC4100 in presence 0.8M NaCl; Strong inhibition [AID71041, Type: other]
View
34
[SID11110845]
 Cytochrome panel assay with activity outcomes [AID1851, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 19 [Homo sapiens] [gi:4503219]
View
35
[SID11110845]
 Cytochrome panel assay with activity outcomes [AID1851, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 19 [Homo sapiens] [gi:4503219]
View
36
[SID103312672]
 TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Betaine: 500 uM) in OCTN2-expressing HRPE cells [AID681713, Type: other]Solute carrier family 22 member 5 [gi:8928242]
View
37
[SID90341438]
Potency 0.1683qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a [AID504332, Type: confirmatory]euchromatic histone-lysine N-methyltransferase 2 [Homo sapiens] [gi:168985070]
View
38
[SID11110845]
Potency qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase [AID959, Type: confirmatory]pyruvate kinase [Leishmania mexicana mexicana] [gi:290753097]
View
39
[SID11110845]
Potency qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase [AID945, Type: confirmatory]pyruvate kinase [Leishmania mexicana mexicana] [gi:290753097]
View
40
[SID90341438]
Potency qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor [AID485366, Type: confirmatory]ADRB2 gene product [Homo sapiens] [gi:4501969]
View
41
[SID90341438]
Potency qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor [AID485366, Type: confirmatory]ADRB2 gene product [Homo sapiens] [gi:4501969]
View
42
[SID90341438]
Potency qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor [AID485366, Type: confirmatory]ADRB2 gene product [Homo sapiens] [gi:4501969]
View
43
[SID90341438]
Potency qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor [AID485366, Type: confirmatory]ADRB2 gene product [Homo sapiens] [gi:4501969]
View
44
[SID11110845]
Potency qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase) [AID1452, Type: confirmatory]arachidonate 12-lipoxygenase, 12S-type [Homo sapiens] [gi:154426292]
View
45
[SID11110845]
Potency qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase) [AID1452, Type: confirmatory]arachidonate 12-lipoxygenase, 12S-type [Homo sapiens] [gi:154426292]
View
46
[SID11110845]
Potency qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase) [AID887, Type: confirmatory]15-lipoxygenase [Homo sapiens] [gi:1832253]
View
47
[SID11110845]
Potency qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase) [AID887, Type: confirmatory]15-lipoxygenase [Homo sapiens] [gi:1832253]
View
48
[SID11110845]
Potency qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2) [AID881, Type: confirmatory]Arachidonate 15-lipoxygenase B [gi:317373425]
View
49
[SID11110845]
Potency qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1 [AID900, Type: confirmatory]caspase-1 isoform alpha precursor [Homo sapiens] [gi:15431328]
View
50
[SID11110845]
Potency qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1 [AID900, Type: confirmatory]caspase-1 isoform alpha precursor [Homo sapiens] [gi:15431328]
View